Literature DB >> 30506719

Clinical significance of long noncoding RNA VIM-AS1 and CTBP1-AS2 expression in type 2 diabetes.

Maryam Erfanian Omidvar1, Hamid Ghaedi2, Faranak Kazerouni1, Saeid Kalbasi3, Mehrnoosh Shanaki1, Ghasem Miraalamy4, Ali Zare2, Ali Rahimipour1.   

Abstract

BACKGROUND/AIMS: The risk of type 2 diabetes (T2D) is determined by a combination of genetic and environmental factors. Multiple studies have proposed that long noncoding RNAs (lncRNAs) are crucial molecules in regulating several biological processes and complex diseases. The study was aimed at investigating the association between the expression levels of lncRNA VIM-AS1, lncRNA CTBP1-AS2, and T2D susceptibility.
METHODS: lncRNA VIM-AS1 and lncRNA CTBP1-AS2 in the peripheral blood mononuclear cell (PBMC) of 100 healthy individuals and 100 T2D patients were collected for Quantitative Real-Time RT-PCR analysis. A logistic regression was performed to understand whether the likelihood of T2D can be predicted based on the expression levels of lncRNA VIM-AS1 and lncRNA CTBP1-AS2. Receiver operating characteristic (ROC) analysis was also performed to determine the statistical analysis of VIM-AS1 and CTBP1-AS2 levels in 200 samples.
RESULTS: Our results display that decreased levels of VIM-AS1 and CTBP1-AS2 in PBMC were associated with diabetes in Iranian population. The logistic regression revealed that Systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), Fasting blood glucose (FBG) and CTBP1-AS2 are substantial predictors of T2D. The ROC analysis of CTBP1-AS2 revealed the area under the ROC curve (AUC) of 0.68 with a sensitivity of 58.7% and specificity of 75.3% in distinguishing nondiabetic from diabetic subjects. The ROC analysis of VIM-AS1 determined AUC of 0.63 with a sensitivity of 56.1% and specificity of 68.37% in distinguishing the two diagnostic groups.
CONCLUSION: lncRNA VIM-AS1 and lncRNA CTBP1-AS2 expression levels are associated with T2D susceptibility.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CTBP1 antisense RNA 2; Peripheral blood mononuclear cell; Type 2 diabetes; VIM antisense RNA 1; long noncoding RNA

Mesh:

Substances:

Year:  2018        PMID: 30506719     DOI: 10.1002/jcb.28206

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

Review 1.  Dysregulated expression of long noncoding RNAs serves as diagnostic biomarkers of type 2 diabetes mellitus.

Authors:  Weiyue Zhang; Juan Zheng; Xiang Hu; Lulu Chen
Journal:  Endocrine       Date:  2019-07-25       Impact factor: 3.633

Review 2.  Long non-coding RNAs: a valuable biomarker for metabolic syndrome.

Authors:  Mohammad Rashidmayvan; Reza Sahebi; Majid Ghayour-Mobarhan
Journal:  Mol Genet Genomics       Date:  2022-07-19       Impact factor: 2.980

3.  LncRNA CTBP1-AS2 Facilitates Gastric Cancer Progression via Regulating the miR-139-3p/MMP11 Axis.

Authors:  Yudan Yang; Ming Gao; Yunpeng Li; Mengyi Li; Qingqing Ma
Journal:  Onco Targets Ther       Date:  2020-11-10       Impact factor: 4.147

4.  LncRNA CTBP1-AS2 is upregulated in osteoarthritis and increases the methylation of miR-130a gene to inhibit chondrocyte proliferation.

Authors:  Hongfei Zhang; Jinglian Li; Weiguang Shao; Naipeng Shen
Journal:  Clin Rheumatol       Date:  2020-05-10       Impact factor: 2.980

5.  LncRNA CTBP1-AS2 regulates miR-216a/ PTEN to suppress ovarian cancer cell proliferation.

Authors:  Kaiying Cui; Genhai Zhu
Journal:  J Ovarian Res       Date:  2020-07-25       Impact factor: 4.234

6.  Long non-coding RNA VIM Antisense RNA 1 (VIM-AS1) sponges microRNA-29 to participate in diabetic retinopathy.

Authors:  Feng Zeng; Gang Luo; Yamei Lu; Zhaotian Zhang; Yuanqing Zhou; Yonging Chen; Zhiyan Zhou
Journal:  Acta Diabetol       Date:  2020-05-23       Impact factor: 4.280

Review 7.  Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes.

Authors:  Nurruzanna Ismail; Noraidatulakma Abdullah; Nor Azian Abdul Murad; Rahman Jamal; Siti Aishah Sulaiman
Journal:  Diagnostics (Basel)       Date:  2021-01-19

8.  The Impact of lncRNAs in Diabetes Mellitus: A Systematic Review and In Silico Analyses.

Authors:  Cristine Dieter; Natália Emerim Lemos; Nathalia Rodrigues de Faria Corrêa; Taís Silveira Assmann; Daisy Crispim
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

9.  Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway.

Authors:  Qiankun Li; Wenjing Yue; Ming Li; Zhipeng Jiang; Zehui Hou; Wei Liu; Ning Ma; Wenchang Gan; Yingru Li; Taicheng Zhou; Wenjing Yue; Shuang Chen
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

10.  Deregulation of lncRNA HIST1H2AG-6 and AIM1-3 in peripheral blood mononuclear cells is associated with newly diagnosed type 2 diabetes.

Authors:  Hui Jiang; Peian Lou; Xiaoluo Chen; Chenguang Wu; Shihe Shao
Journal:  BMC Med Genomics       Date:  2021-06-06       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.